3T Ophthalmics

3T Ophthalmics is a clinical-stage biotechnology company focused on the development of novel drug delivery technologies for the treatment of retinal diseases. The company's core technology is the 3T Suprachoroidal Delivery System, which enables Targeted, Tailored, and Timed delivery of therapeutics to the posterior segment of the eye. This approach aims to maximize drug concentration at the site of disease while minimizing exposure to non-target tissues, potentially reducing side effects like cataracts and increased intraocular pressure. Their lead candidate, 3T-011, is currently being evaluated for indications such as diabetic macular edema and retinal vein occlusion. 3T Ophthalmics was founded by leading retinal specialists to address the limitations of current intravitreal injection methods.